• Ziprasidone Augmentation in Escitalopram-Resistant Depressio

  2026-05-25

  This article examines a double-blind trial evaluating ziprasidone as adjunctive therapy for major depressive disorder (MDD) patients with inadequate response to escitalopram, focusing on anxious versus nonanxious subgroups. The findings reveal that while ziprasidone augmentation improves depressive symptoms similarly in both groups, its anxiolytic effects are not clinically significant for patients with prominent anxiety.

• 2-Deoxy-D-glucose: Applied Workflows for Glycolysis Inhibiti

  2026-05-25

  2-Deoxy-D-glucose (2-DG) is redefining cancer and virology research with precision glycolysis inhibition. This guide delivers advanced workflow enhancements, troubleshooting insights, and translational strategies—linking metabolic stress induction to breakthrough immunometabolic discoveries.

• PTBP2 Attenuation Enables Efficient Fibroblast-to-Neuron Con

  2026-05-24

  This study demonstrates that reducing PTBP2 expression significantly enhances the direct reprogramming of human skin fibroblasts into functional neurons by promoting neuron-specific alternative splicing, especially via RBFOX3 regulation. These insights clarify a crucial molecular barrier in neuronal reprogramming and highlight new strategies for studying neurodegenerative disease mechanisms.

• CD44-Driven Metabolic Rewiring in IDH-Mutant Leukemia

  2026-05-23

  This study uncovers how CD44 upregulation supports high-level 2-hydroxyglutarate production in IDH-mutant leukemia by reprogramming cellular metabolism to sustain NADPH generation. Targeting the CD44 axis, especially in combination with mutant IDH1 inhibition, suggests a promising strategy to overcome therapy resistance in acute myeloid leukemia (AML).

• Monomethyl Auristatin E (MMAE): Precision Payload and Tumor

  2026-05-22

  Explore Monomethyl auristatin E (MMAE) as a powerful antimitotic ADC payload in cancer therapy. This in-depth analysis reveals unique insights into its role in overcoming tumor plasticity and resistance, setting it apart from prior reviews.

• FITC Goat Anti-Mouse IgG (H+L) Antibody: Applied Immunofluor

  2026-05-22

  The FITC Goat Anti-Mouse IgG (H+L) Antibody unlocks high-sensitivity and reproducible mouse IgG detection across immunofluorescence and flow cytometry workflows. By enabling robust signal amplification and seamless protocol integration, this APExBIO reagent stands out for its reliability in advanced experimental designs.

• Palonosetron Hydrochloride: Innovations in CINV Prevention

  2026-05-21

  Ruhlmann & Herrstedt's review critically examines palonosetron hydrochloride as an advanced 5-HT3 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting (CINV). Their synthesis highlights palonosetron’s unique pharmacologic properties, prolonged efficacy, and improved outcomes in acute and delayed emesis, with implications for antiemetic protocol optimization.

• Dynasore (SKU A1605): Optimizing Endocytosis Research Reliab

  2026-05-21

  This article delivers evidence-backed, scenario-driven guidance for cell biologists and biomedical researchers using Dynasore (SKU A1605) as a dynamin GTPase inhibitor in endocytosis, vesicle trafficking, and cancer research. Drawing from recent literature and practical laboratory challenges, it highlights protocol optimization, reproducibility, and vendor selection considerations.

• (-)-Norepinephrine (+)-bitartrate: Translational Insights fo

  2026-05-20

  Explore how (-)-Norepinephrine (+)-bitartrate advances cardiovascular research by bridging translational dosing insights with mechanistic adrenergic pathway analysis. This article uniquely connects preclinical assay design with clinical vasopressor evidence, empowering researchers to optimize experimental rigor.

• Mitochondrial Potential Assays: New Frontiers for Translatio

  2026-05-20

  Explore how Tetramethylrhodamine ethyl ester perchlorate (TMRE, SKU: C8197) from APExBIO is redefining mitochondrial membrane potential assays for translational researchers. This article bridges mechanistic discovery—specifically caspase-3/NDUFS1-driven mitochondrial dysfunction in toxin-induced hepatotoxicity—with actionable guidance for experimental design. We contextualize TMRE’s advantages amid the evolving landscape of mitochondria-focused diagnostics and therapeutic monitoring, and articulate strategic insights for multi-disciplinary teams advancing mitochondrial dysfunction research.

• Pharmacogenomics of Chloroquine and Hydroxychloroquine: Evid

  2026-05-19

  This article analyzes the systematic review by Biswas and Sukasem, which synthesizes the pharmacogenomic evidence for chloroquine and hydroxychloroquine metabolism, safety, and efficacy. The findings emphasize the clinical importance of CYP450 genetic variants in predicting patient risk phenotypes, advocating for targeted pharmacogenetic implementation in therapeutic strategies.

• Cy3 Goat Anti-Mouse IgG (H+L) Antibody: Technical Use Guide

  2026-05-19

  The Cy3 Goat Anti-Mouse IgG (H+L) Antibody provides sensitive, specific detection of mouse primary antibodies in immunofluorescence, flow cytometry, and western blot workflows. It is best suited for applications requiring robust signal amplification and clear visualization, but should not be used in diagnostic or clinical settings. Researchers should follow storage and handling best practices to preserve antibody integrity.

• LpqH-Tagged Microvesicles Enable Targeted mRNA Delivery to M

  2026-05-18

  Huo et al. introduce LpqH-tagged microvesicles as a novel mRNA vaccine carrier platform that achieves highly specific delivery and robust immune activation in macrophages. This advance addresses key challenges in mRNA vaccine targeting, showing superior encapsulation and immunogenicity compared to lipid nanoparticles.

• Sorafenib in Hepatocellular Carcinoma Models: Mechanisms, Pr

  2026-05-18

  Explore how Sorafenib (BAY-43-9006) advances hepatocellular carcinoma research through its multikinase inhibition and impact on tumor lipid metabolism. This article dives deeper than standard guides, integrating new mechanistic insights for cancer biology research.

• Baicalein–Copper Nanoassemblies Trigger Cuproptosis for Canc

  2026-05-17

  This study reports a baicalein–copper nanoassembly (BCB) that synergizes chemodynamic and photodynamic therapy to induce cuproptosis and robust ROS production for targeted cancer treatment. The platform’s bone-penetrating ability and TME-responsiveness offer a promising strategy for addressing therapeutic resistance in bone-metastatic and primary tumors.

406 records 14/28 page Previous Next First page 上5页 1112131415 下5页 Last page